Axa
MXCT icon

Axa’s MaxCyte MXCT Stock Holding History

Axa’s Portfolio MXCT Stock Details MXCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,202,378
Closed -$4.8M – 696
2025
Q2 		$4.8M Buy
2,202,378
+1,215,481
+123% +$2.94M 0.01% 572
2025
Q1 		$2.69M Hold
986,897
– – 0.01% 682
2024
Q4 		$4.11M Buy
+986,897
New +$3.73M 0.01% 587

Other funds holding MXCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCM
Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.05B AUM 22.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VP
Vitruvian Partners London, United Kingdom $201M AUM 10.44% 1-Year Est. Return
MA
Mudita Advisors London, United Kingdom $481M AUM 73.74% 1-Year Est. Return
AIM
AXA Investment Managers Puteaux, France $37.1B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Axa's MXCT Position: Q3 2025 in Review

Axa sold out of MaxCyte (MXCT) in Q3 2025, closing a stake of 2,202,378 shares — an estimated $4.8M sold.

Axa first reported a position in MXCT in Q4 2024 and held it in 3 quarters. The position peaked at $4.8M in Q2 2025. 112 funds tracked by Wall St. Rank hold MXCT as of Q3 2025.

  • Axa reported no remaining MaxCyte position as of Q3 2025 after selling out during the quarter.
  • Axa sold 2,202,378 MaxCyte shares in Q3 2025, an estimated $4.8M.
  • Axa first reported a position in MaxCyte in Q4 2024 and held it in 3 quarters.
  • Axa's MaxCyte position peaked at $4.8M in Q2 2025.
  • 112 funds tracked by Wall St. Rank held MaxCyte as of Q3 2025.

Based on Axa's 13F filing for Q3 2025, filed 14 Nov 2025.